Item # Length Source of Standard Year Implemented Version Implemented Year Retired Version Retired
470 1 NAACCR

NAACCR XML: Tumor.morphCodingSysCurrent

Description

Code that best describes how morphology is currently coded. If converted, this field shows the system it is converted to. An update or new Morphology Coding System code incorporates all previous coding updates.

Codes

1ICD-O, First Edition
2ICD-O, 1986 Field Trial
3ICD-O, 1988 Field Trial
4ICD-O, Second Edition
5ICD-O, Second Edition, plus REAL lymphoma codes effective 1/1/1995
6ICD-O, Second Edition, plus FAB codes effective 1/1/1998
7ICD-O, Third Edition
8ICD-O, Third Edition, plus 2008 WHO hematopoietic/lymphoid new terms used for conditions diagnosed 1/1/2010\*
9Other
AICD-O, Third Edition, plus WHO new terms used for conditions, effective 1/1/2018\*\*
BICD-O 3.2, effective 1/1/2021
CICD-O-3.2, plus, WHO new terms used for conditions, effective 1/1/2022\*\*\*
DICD-O-3.2, plus, WHO new terms used for conditions, effective 1/1/2023\*\*\*
EICD-O-3.2, plus, WHO new terms used for conditions, effective 1/1/2024\*\*\*\*

Note:
 
* These changes were based on the terms of the World Health Organization’s (WHO) fourth edition of the following publications:

For details including the list of terms included, refer to the link to the NAACCR ICD-O-3 Implementation Guidelines document, effective for 2014 cases: https://20tqtx36s1la18rvn82wcmpn-wpengine.netdna-ssl.com/wp-content/uploads/2016/11/ICD-O-3-Implementation-Guide-FINAL.pdf.

**These changes are based on the terms of the World Health Organization’s (WHO) fourth edition of the following publications:

For details including the list of terms included, refer to the link to the NAACCR ICD-O-3 Implementation Guidelines document, effective for 2018 cases: <https://20tqtx36s1la18rvn82wcmpn-wpengine.netdna-ssl.com/wp-content/uploads/2018/01/Updated-Jan-10-2018-ICD-O-3-Guidelines-v2.pdf>.

 
*** These changes are based on the terms of the World Health Organization’s (WHO) fifth edition of the following publications:

****These changes are based on the terms of the World Health Organization’s (WHO) fifth edition of the following publication: 

WHO Classification of Tumors of the Urinary and Male Genital Organs 5th Ed (2022).

 
For details including the list of terms included, refer to the link to the NAACCR ICD-O-3 Implementation Guidelines document, effective for 2022 cases: TBD.